目的:比较thulium激光前列腺摘除术(ThuLEP)与等离子前列腺电切术(PKRP)治疗BPH的疗效。
方法:我们回顾性分析160例接受ThuLEP治疗的BPH患者的病历(观察组,n=80)或PKRP(对照组,n=80)于2021年1月至2023年12月在我院就诊。我们记录了手术时间,膀胱冲洗时间,导管保留时间,住院时间,术后并发症,术前和术后最大尿流率(Qmax),残余尿量(PVR),前列腺特异性抗原(PSA)和前列腺体积,然后比较两组患者之间获得的数据。
结果:与对照组相比,观察组患者手术时间明显缩短([67.25±7.24]vs[60.10±5.15]min,P<0.05),膀胱冲洗时间([46.90±10.77]vs[43.24±6.65]h,P<0.05),置管时间([5.60±1.31]vs[5.03±1.24]d,P<0.05)和住院时间([7.31±2.00]vs[6.55±1.67]d,P<0.05),更高的Qmax([18.50±1.24]vs[20.68±1.45]ml/s,P<0.05),较低的PVR([12.10±3.53]对[10.82±3.10]ml,P<0.05),PSA([4.60±0.78]vs[3.38±0.40]μg/L,P<0.05)和前列腺体积([25.35±6.46]vs[20.12±5.13]ml,P<0.05)术后3个月,但术后并发症总发生率差异无统计学意义(7.50%[6/80]vs5.00%[4/80],P>0.05)。
结论:ThuLEP,以其效果显著的优点,手术和住院时间短,显著改善尿流动力学和前列腺功能,BPH的治疗值得临床推广。
OBJECTIVE: To compare
thulium laser enucleation of the prostate (ThuLEP) with plasma kinetic resection of the prostate (PKRP) in the treatment of BPH.
METHODS: We retrospectively analyzed the medical records of 160 cases of BPH treated by ThuLEP (the observation group, n = 80) or PKRP (the control group, n = 80) in our hospital from January 2021 to December 2023. We recorded the operation time, bladder irrigation time, catheter retention time, hospitalization time, postoperative complications, and pre- and postoperative maximum urinary flow rate (Qmax), residual urine volume (PVR), prostate-specific antigen (PSA) and prostate volume, followed by comparison of the data obtained between the two groups of patients.
RESULTS: Compared with the controls, the patients of the observation group showed significantly shorter operation time ([67.25 ± 7.24] vs [60.10 ± 5.15] min, P< 0.05), bladder irrigation time ([46.90 ± 10.77] vs [43.24 ± 6.65] h, P< 0.05), catheterization time ([5.60 ± 1.31] vs [5.03 ± 1.24] d, P< 0.05) and hospitalization time ([7.31 ± 2.00] vs [6.55 ± 1.67] d, P< 0.05), higher Qmax ([18.50 ± 1.24] vs [20.68 ± 1.45] ml/s, P< 0.05), lower PVR ([12.10 ± 3.53] vs [10.82 ± 3.10] ml, P< 0.05), PSA ([4.60 ± 0.78] vs [3.38 ± 0.40] μg/L, P< 0.05) and prostate volume ([25.35 ± 6.46] vs [20.12 ± 5.13] ml, P< 0.05) at 3 months after surgery, but no statistically significant difference in the total incidence of postoperative complications (7.50% [6/80] vs 5.00% [4/80], P > 0.05).
CONCLUSIONS: ThuLEP, with its advantages of notable effect, short operation and hospitalization time, significant improvement of urinary flow dynamics and prostate function, deserves clinical promotion for the treatment of BPH.